Seroatlas · Human Serome Atlas

CRIPTO

Protein Cripto

Also known as: CR, CR-1, Cripto-1, TDGF1, TDGF1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P13385
Gene: CRIPTO
Ensembl: ENSG00000241186
Chromosome: 3
Canonical length: 188 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Vesicles
Secretome location: Secreted in other tissues

OverviewNCBI Gene

This gene encodes an epidermal growth factor-related protein that contains a cripto, FRL-1, and cryptic domain. The encoded protein is an extracellular, membrane-bound signaling protein that plays an essential role in embryonic development and tumor growth. Mutations in this gene are associated with forebrain defects. Pseudogenes of this gene are found on chromosomes 2, 3, 6, 8, 19 and X. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010]

Canonical amino-acid sequenceUniProt

188 residues, UniProt reviewed canonical sequence.

>P13385|CRIPTO
     1  MDCRKMARFS YSVIWIMAIS KVFELGLVAG LGHQEFARPS RGYLAFRDDS IWPQEEPAIR
    61  PRSSQRVPPM GIQHSKELNR TCCLNGGTCM LGSFCACPPS FYGRNCEHDV RKENCGSVPH
   121  DTWLPKKCSL CKCWHGQLRC FPQAFLPGCD GLVMDEHLVA SRTPELPPSA RTTTFMLVGI
   181  CLSIQSYY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CRIPTO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 20 nTPM

Expression across tissuesHPA

Tissue

spleen: 20 nTPM
kidney: 19 nTPM
thymus: 14 nTPM
ovary: 9.4 nTPM
rectum: 4.3 nTPM
adrenal gland: 3.6 nTPM

Single-cell type

granulosa cells: 23 nCPM
medullary thymic epithelial cells: 9.6 nCPM
ovarian stromal cells: 5.6 nCPM
early spermatids: 5.2 nCPM
loop of henle epithelial cells: 3.5 nCPM
retinal horizontal cells: 2 nCPM

Immune cell

basophil: 0.6 nTPM
neutrophil: 0.6 nTPM
NK-cell: 0.3 nTPM
naive B-cell: 0.2 nTPM
classical monocyte: 0.1 nTPM
eosinophil: 0.1 nTPM

Brain region

thalamus: 6.9 nTPM
amygdala: 5.4 nTPM
pons: 5.2 nTPM
medulla oblongata: 5 nTPM
cerebellum: 4.6 nTPM
cerebral cortex: 4.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.92
gnomAD pLI: 0
DepMap mean gene effect: -0.44
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CRIPTO in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

ACVR1B

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CRIPTO as an antibody target. Whether an autoantibody or antibody against CRIPTO could matter depends on whether native CRIPTO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CRIPTO is annotated at the cell surface, where native CRIPTO is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CRIPTO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...